UY33202A - Proteínas de unión a cd127 - Google Patents

Proteínas de unión a cd127

Info

Publication number
UY33202A
UY33202A UY0001033202A UY33202A UY33202A UY 33202 A UY33202 A UY 33202A UY 0001033202 A UY0001033202 A UY 0001033202A UY 33202 A UY33202 A UY 33202A UY 33202 A UY33202 A UY 33202A
Authority
UY
Uruguay
Prior art keywords
proteins
union
antigen
binding proteins
diseases
Prior art date
Application number
UY0001033202A
Other languages
English (en)
Inventor
Kirby Ian
Alexander H Taylor
Thomas Matthew Webb
Xue Yu
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY33202A publication Critical patent/UY33202A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan proteínas de unión a antígeno que se unen al receptor de IL-7 humano (CD127). Las proteínas de unión a antígeno típicamente son anticuerpos, y son útiles en el tratamiento de enfermedades o trastornos en seres humanos, particularmente enfermedades autoinmunes tales como la esclerosis múltiple.
UY0001033202A 2010-01-28 2011-01-26 Proteínas de unión a cd127 UY33202A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29901010P 2010-01-28 2010-01-28

Publications (1)

Publication Number Publication Date
UY33202A true UY33202A (es) 2011-08-31

Family

ID=44320081

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033202A UY33202A (es) 2010-01-28 2011-01-26 Proteínas de unión a cd127

Country Status (25)

Country Link
US (2) US9150653B2 (es)
EP (1) EP2528947A4 (es)
JP (1) JP5850860B2 (es)
KR (1) KR20130028055A (es)
CN (1) CN102812046B (es)
AR (1) AR080027A1 (es)
AU (1) AU2011209713B2 (es)
BR (1) BR112012018914A2 (es)
CA (1) CA2787070A1 (es)
CL (1) CL2012002081A1 (es)
CO (1) CO6592067A2 (es)
CR (1) CR20120404A (es)
EA (1) EA023700B1 (es)
IL (1) IL220899A (es)
MA (1) MA34004B1 (es)
MX (1) MX339083B (es)
MY (1) MY160590A (es)
NZ (1) NZ601271A (es)
PE (2) PE20170687A1 (es)
SG (1) SG182590A1 (es)
TW (1) TWI489996B (es)
UA (1) UA104663C2 (es)
UY (1) UY33202A (es)
WO (1) WO2011094259A2 (es)
ZA (1) ZA201205624B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2016059512A1 (en) 2014-10-18 2016-04-21 Pfizer Inc. Anti-il-7r antibody compositions
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
WO2017120479A1 (en) * 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
ES2737307T3 (es) 2016-02-29 2020-01-13 Ose Immunotherapeutics Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
NZ753213A (en) * 2016-12-09 2022-05-27 Ose Immunotherapeutics Antibodies and polypeptides directed against cd127
WO2019136180A2 (en) * 2018-01-04 2019-07-11 Avidity Biosciences Llc Heteroduplex nucleic acid molecules and uses thereof
SG11202107951YA (en) * 2019-01-22 2021-08-30 Bristol Myers Squibb Co Antibodies against il-7r alpha subunit and uses thereof
CN114466864A (zh) 2019-06-21 2022-05-10 索瑞索制药公司 多肽
CN114514243A (zh) 2019-06-21 2022-05-17 索瑞索制药公司 多肽
MX2021015762A (es) 2019-06-21 2022-04-18 Sorriso Pharmaceuticals Inc Composiciones.
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1990015870A1 (en) 1989-06-15 1990-12-27 Immunex Corporation Interleukin-7 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
JP2000510692A (ja) 1996-05-04 2000-08-22 ゼネカ リミテッド Ｃｅａに対するモノクローナル抗体、その抗体を含む結合体、およびａｄｅｐｔシステムにおけるそれらの治療的使用
ES2274566T3 (es) 1997-02-07 2007-05-16 MERCK & CO., INC. Genes gag del vih sinteticos.
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000062071A1 (de) 1999-04-13 2000-10-19 Wilex Ag Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
CA2421447C (en) 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
CA2573745A1 (en) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
WO2006052660A2 (en) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Il-7 receptor blockade to suppress immunity
BRPI0719409A2 (pt) * 2006-12-18 2014-02-11 Genentch Inc "regiões variáveis da cadeia pesada ("vh"), sequências da cadeia vh, ácido nucléico, vetor, célula, anticorpos, uso do anticorpo, método para produzir um anticorpo, anticorpo anti-notch3 e forma humanizada do anticorpo"
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US20090226442A1 (en) * 2008-01-22 2009-09-10 Biogen Idec Ma Inc. RON antibodies and uses thereof
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos

Also Published As

Publication number Publication date
EP2528947A4 (en) 2013-09-18
MA34004B1 (fr) 2013-02-01
US9150653B2 (en) 2015-10-06
SG182590A1 (en) 2012-08-30
CL2012002081A1 (es) 2012-12-14
CN102812046A (zh) 2012-12-05
CA2787070A1 (en) 2011-08-04
BR112012018914A2 (pt) 2017-07-25
MY160590A (en) 2017-03-15
US20110200585A1 (en) 2011-08-18
EP2528947A2 (en) 2012-12-05
AR080027A1 (es) 2012-03-07
AU2011209713A1 (en) 2012-09-13
US20120282254A1 (en) 2012-11-08
MX2012008765A (es) 2012-09-07
UA104663C2 (en) 2014-02-25
KR20130028055A (ko) 2013-03-18
CN102812046B (zh) 2015-02-25
IL220899A (en) 2017-08-31
WO2011094259A2 (en) 2011-08-04
MX339083B (es) 2016-04-01
TW201136607A (en) 2011-11-01
EA201290589A1 (ru) 2013-05-30
CO6592067A2 (es) 2013-01-02
PE20170687A1 (es) 2017-06-13
PE20121702A1 (es) 2012-12-14
EA023700B1 (ru) 2016-07-29
TWI489996B (zh) 2015-07-01
JP2013517799A (ja) 2013-05-20
NZ601271A (en) 2014-09-26
JP5850860B2 (ja) 2016-02-03
US8940303B2 (en) 2015-01-27
WO2011094259A3 (en) 2011-09-29
AU2011209713B2 (en) 2014-04-03
ZA201205624B (en) 2014-01-29
CR20120404A (es) 2012-10-04
IL220899A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
UY33202A (es) Proteínas de unión a cd127
UY34995A (es) Formulaciones de anticuerpo y proteína
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
EA201591059A1 (ru) МОДУЛЯТОРЫ СИРОТСКИХ ГАММА-РЕЦЕПТОРОВ РЕТИНОИДОВ (RORγ) ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
EA201370081A1 (ru) Антитела к cd48 и их применение
IN2015DN02032A (es)
BR112016023948A2 (pt) proteínas fc multiméricas
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201500314A1 (ru) Лекарственные формы энзалутамида
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
UY34782A (es) Anticuerpos humanos para fel d1 y métodos para usarlos.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
JO3547B1 (ar) أجسام مضادة ضد تخليق جدار الخلية واستعمالاتها
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
MX365403B (es) Peptidos y metodos para usarlos.
GB201109238D0 (en) Antibodies
MX2013001267A (es) ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191209